FindTrial
Sign In

Paromomycin

DRUG9 trials

Sponsors

FDA Office of Orphan Products Development, Banaras Hindu University, U.S. Army Medical Research and Development Command, Drugs for Neglected Diseases, Fundacion Nacional de Dermatologia

Conditions

Cutaneous LeishmaniasisCutaneous Leishmaniasis, AmericanDientamoeba Fragilis InfectionLeishmaniasis, CutaneousPKDL - Post-Kala-Azar Dermal LeishmanioidPrimary Visceral LeishmaniasisTuberculosis, PulmonaryVisceral Leishmaniasis

Phase 2

Short Course Regimens for Treatment of PKDL (Sudan)
NCT03399955
Drugs for Neglected DiseasesPKDL - Post-Kala-Azar Dermal Leishmanioid
Start: 2018-05-09End: 2022-05-01Target: 110Updated: 2020-01-18
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis
CompletedNCT03829917
Fundacion Nacional de DermatologiaCutaneous Leishmaniasis, American
Start: 2019-02-01End: 2020-12-31Updated: 2021-02-02
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
CompletedNCT05957978
Drugs for Neglected DiseasesPrimary Visceral Leishmaniasis
Start: 2024-03-29End: 2025-11-13Updated: 2025-12-18

Phase 3

An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
CompletedNCT00629031
Banaras Hindu UniversityVisceral Leishmaniasis
Start: 2008-02-29End: 2008-08-31Updated: 2008-09-12
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
CompletedNCT01790659
U.S. Army Medical Research and Development CommandCutaneous Leishmaniasis
Start: 2013-05-31End: 2016-01-31Updated: 2018-02-14
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
CompletedNCT03129646
Drugs for Neglected DiseasesVisceral Leishmaniasis
Start: 2018-01-24End: 2020-12-11Updated: 2024-02-29

Unknown Phase

Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis
CompletedNCT00004444
FDA Office of Orphan Products DevelopmentTuberculosis, Pulmonary
Start: 1994-11-30End: 2001-01-31Target: 24Updated: 2015-03-25
Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis
NCT01641796
U.S. Army Medical Research and Development CommandLeishmaniasis, Cutaneous
Updated: 2020-05-15
Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults
RecruitingNCT06907498
Sheba Medical CenterDientamoeba Fragilis Infection
Start: 2024-01-22End: 2026-12-31Target: 60Updated: 2025-04-02

Related Papers

Differences in the Cellular Immune Response during and after Treatment of Sudanese Patients with Post-kala-azar Dermal Leishmaniasis, and Possible Implications for Outcome.
2024-07-152 citations
Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study
PLoS neglected tropical diseases2023-11-2130 citations
Efficacy and safety of 14-day treatment with paromomycin and miltefosine for primary visceral leishmaniasis in eastern Africa: non-inferiority trial
2023-01-01
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
Clinical Infectious Diseases2022-09-2764 citations
Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.
2009-09-0130 citations